Conversely, anti-EGFR therapy provides benefit only in RAS and BRAF wild-type patients, excluding approximately 60% of CRC cases due to mutation-driven intrinsic resistance (33, 244). The gene discussed is BRAF; the disease is colorectal carcinoma.